- Delgocitinib 0.5% ointment is associated with clinical efficacy and good safety in patients with moderate to severe atopic dermatitis (AD), according to results from a phase 3 trial.
Why this matters
- Novel topical treatment options with a good efficacy-safety profile are needed for AD.
- Delgocitinib was associated with a greater least-squares mean percentage change from baseline compared with vehicle at 4 weeks: −44.3% vs 1.7% (P<.001>
- Compared with vehicle, delgocitinib was associated with higher rates of patients achieving ≥50% improvement on:
- Modified Eczema Area and Severity Index (mEASI-50): 51.9% vs 11.5% (P<.001>
- mEASI-75: 26.4% vs 5.8% (P<.01>
- The most common adverse event was nasopharyngitis (19.5%).
- 158 patients with moderate to severe AD were randomly assigned to receive delgocitinib 0.5% ointment (n=106) or vehicle (n=52), and followed for efficacy and safety outcomes.
- Funding: Japan Tobacco Inc.
- Short trial duration.